Clearmind Accounts Payable vs Other Stockholder Equity Analysis
| CMND Stock | USD 1.33 0.01 0.75% |
Clearmind Medicine financial indicator trend analysis is way more than just evaluating Clearmind Medicine Common prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Clearmind Medicine Common is a good investment. Please check the relationship between Clearmind Medicine Accounts Payable and its Other Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Accounts Payable vs Other Stockholder Equity
Accounts Payable vs Other Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Clearmind Medicine Common Accounts Payable account and Other Stockholder Equity. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Clearmind Medicine's Accounts Payable and Other Stockholder Equity is 0.83. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Clearmind Medicine Common, assuming nothing else is changed. The correlation between historical values of Clearmind Medicine's Accounts Payable and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Clearmind Medicine Common are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Accounts Payable i.e., Clearmind Medicine's Accounts Payable and Other Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.83 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Accounts Payable
An accounting item on the balance sheet that represents Clearmind Medicine obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Clearmind Medicine Common are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Other Stockholder Equity
Most indicators from Clearmind Medicine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Clearmind Medicine Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Clearmind Medicine's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 414.2 K, whereas Enterprise Value Over EBITDA is forecasted to decline to 0.40.
Clearmind Medicine fundamental ratios Correlations
Click cells to compare fundamentals
Clearmind Medicine Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Clearmind Medicine fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 512.7K | 5.2M | 1.1M | 4.3M | 5.0M | 5.2M | |
| Total Current Liabilities | 13.4K | 357.2K | 2.6M | 3.6M | 4.2M | 4.4M | |
| Total Stockholder Equity | 499.3K | 4.8M | (1.5M) | 1.4M | 1.6M | 1.6M | |
| Net Tangible Assets | 133.8K | 319.6K | 4.6M | (1.7M) | (1.9M) | (1.8M) | |
| Retained Earnings | (539.7K) | (4.4M) | (13.8M) | (13.6M) | (12.3M) | (11.7M) | |
| Accounts Payable | 4.0K | 281.5K | 1.0M | 448.2K | 515.4K | 541.2K | |
| Cash | 329.8K | 4.6M | 175.8K | 3.9M | 4.5M | 4.7M | |
| Total Liab | 13.4K | 357.2K | 2.6M | 3.6M | 4.2M | 4.4M | |
| Total Current Assets | 333.0K | 4.9M | 593.3K | 4.2M | 4.8M | 5.1M | |
| Common Stock | 891.7K | 7.9M | 9.2M | 12.4M | 14.3M | 15.0M | |
| Other Current Liab | 6.1K | 6.7K | 1.6M | 3.2M | 3.6M | 3.8M | |
| Property Plant And Equipment Net | 179.7K | 20.6K | 66.4K | 1.2K | 1.1K | 1.1K | |
| Net Debt | (329.8K) | (4.6M) | (123.4K) | (3.9M) | (3.5M) | (3.4M) | |
| Non Current Assets Total | 179.7K | 238.6K | 534.7K | 115.3K | 132.6K | 224.1K | |
| Cash And Short Term Investments | 329.8K | 4.6M | 440.2K | 4.0M | 4.6M | 4.8M | |
| Net Receivables | 3.1K | 129.8K | 133.7K | 174.6K | 200.8K | 210.8K | |
| Liabilities And Stockholders Equity | 512.7K | 5.2M | 1.1M | 4.3M | 5.0M | 5.2M | |
| Non Current Liabilities Total | 7.6K | 12.7K | 5.3K | 348.9K | 2.0M | 0.0 | |
| Common Stock Shares Outstanding | 18.1K | 30.9K | 43.3K | 202.5K | 232.9K | 244.5K | |
| Other Stockholder Equity | 369.7K | 2.9M | 2.5M | 2.6M | 3.0M | 1.6M | |
| Net Invested Capital | 499.3K | 4.8M | (1.5M) | 983.5K | 885.1K | 785.4K | |
| Capital Stock | 891.7K | 7.9M | 9.2M | 17.1M | 19.7M | 20.7M | |
| Net Working Capital | 319.6K | 4.6M | (2.0M) | 824.8K | 742.3K | 579.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearmind Medicine Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Return On Assets (0.58) | Return On Equity (2.68) |
The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.